{"title": "Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1", "doi": "10.1101/2020.03.09.20033217", "citation_id": "2020.03.09.20033217v2", "date": "2020-03-13", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.09.20033217", "abstract": "<p>A novel human coronavirus, now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, referred to as HCoV-19 here) that emerged in Wuhan, China in late 2019 is now causing a pandemic.  Here, we analyze the aerosol and surface stability of HCoV-19 and compare it with SARS-CoV-1, the most closely related human coronavirus.2 We evaluated the stability of HCoV-19 and SARS-CoV-1 in aerosols and on different surfaces and estimated their decay rates using a Bayesian regression model</p>", "twitter_description": "A novel human coronavirus, now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, referred to as HCoV-19 here) that emerged in Wuhan, China in late 2019 is now causing a pandemic. Here, we analyze the aerosol and surface stability of HCoV-19 and compare it with SARS-CoV-1, the most closely related human coronavirus.2 We evaluated the stability of HCoV-19 and SARS-CoV-1 in aerosols and on different surfaces and estimated their decay rates using a Bayesian regression model\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nThis research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). JOL-S and AG were supported by the Defense Advanced Research Projects Agency DARPA PREEMPT # D18AC00031, and JOL-S was supported by the U.S. National Science Foundation (DEB-1557022) and the Strategic Environmental Research and Development Program (SERDP, RC\u20102635) of the U.S. Department of Defense. \n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\ndata is available upon request", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.09.20033217v2.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.09.20033217v2", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.09.20033217v2.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/13/2020.03.09.20033217.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.09.20033217v2", "access_rights": "restricted", "authors": ["Neeltje van Doremalen", "Trenton Bushmaker", "Dylan Morris", "Myndi Holbrook", "Amandine Gamble", "Brandi Williamson", "Azaibi Tamin", "Jennifer Harcourt", "Natalie Thornburg", "Susan Gerber", "Jamie Lloyd-Smith", "Emmie de Wit", "Vincent Munster"]}